Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

HCMBullishIndustry Newsnews

High materiality8/10

Orpathys-Tagrisso combo shows 45% progression reduction in MET-driven EGFR-mutant NSCLC

Oct 25, 2026, 8:12 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive trial efficacy supports a valuation uplift from potential royalties, milestones, and expanded indications; near-term catalysts include further trial readouts and regulatory milestones.

AI summary

What happened, with direct paths to the underlying reporting

Orpathys (savolitinib) with Tagrisso (osimertinib) cut the risk of progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutant lung cancer after Tagrisso progression. The readout strengthens Hutchmed's collaboration with AstraZeneca and could unlock royalties, broadened indications, and milestones, offering near-term upside for HCM investors if validated in follow-on trials.

Orpathys plus Tagrisso reduces progression risk by 45%.
Death risk drops 32% in MET-driven EGFR-mutant NSCLC.
Study focuses on patients after Tagrisso progression.
Hutchmed (HCM) could gain royalties and expanded collaboration.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Orpathys-Tagrisso combo shows 45% progression reduction in MET-driven EGFR-mutant NSCLC

Positive China Trial Data Moves HUTCHMED Closer To Rare Blood Disorder Drug Filing In 2026

Hutchmed's Oncology Revenue Hits $271.5 Million, Rising 65% On Fruzaqla Strength